CV Sciences (CVSI) Interest Expenses (2011 - 2026)
CV Sciences (CVSI) reported Interest Expenses of $93000.0 for Q1 2026, down 38.41% on a YoY basis from $151000.0 in Q1 2025, and up 124.35% sequentially from -$382000.0 in Q4 2025.
CV Sciences (CVSI) Interest Expenses (2011 - 2026) Analysis & Trends
CV Sciences (CVSI) has 16 years of Interest Expenses data on file, last reported at $93000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest Expenses fell 38.41% year-over-year to $93000.0; the trailing twelve-month figure through Mar 2026 stood at -$44000.0 (down 112.22% YoY), and the FY2025 full-year result was $13.4 million, down 1.58% from the prior year.
- Interest Expenses rose to $93000.0 in Q1 2026, from -$382000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $17.0 million in Q4 2023 to a low of -$382000.0 in Q4 2025.
- A 5-year average of $1.4 million and a median of $231500.0 in 2023 frame the typical range for Interest Expenses.
- Peak annual rise in Interest Expenses reached 278.26% in 2025, while the deepest fall reached 506.38% in 2025.
- Tracing CVSI's Interest Expenses over 5 years: stood at $600000.0 in 2022, then surged by 2737.17% to $17.0 million in 2023, then tumbled by 99.45% to $94000.0 in 2024, then tumbled by 506.38% to -$382000.0 in 2025, then soared by 124.35% to $93000.0 in 2026.
- Business Quant data shows CVSI's Interest Expenses at $93000.0 in Q1 2026, -$382000.0 in Q4 2025, and $435000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 944.51 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.77 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 2.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.21 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 590.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | 93,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93,000.00 |
| Mar 31, 2026 | 93,000.00 |
| Dec 31, 2025 | -382,000.00 |
| Dec 31, 2025 | -382,000.00 |
| Sep 30, 2025 | 435,000.00 |
| Sep 30, 2025 | 435,000.00 |
| Jun 30, 2025 | 504,000.00 |
| Jun 30, 2025 | 504,000.00 |
| Mar 31, 2025 | 151,000.00 |
| Mar 31, 2025 | 151,000.00 |
| Dec 31, 2024 | 94,000.00 |
| Dec 31, 2024 | 94,000.00 |
| Sep 30, 2024 | 115,000.00 |
| Sep 30, 2024 | 115,000.00 |
| Jun 30, 2024 | 230,000.00 |
| Jun 30, 2024 | 230,000.00 |
| Mar 31, 2024 | 164,000.00 |
| Mar 31, 2024 | 164,000.00 |
| Dec 31, 2023 | 17.02 Mn |
| Dec 31, 2023 | 17.02 Mn |